NBIX Neurocrine Biosciences Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: NBIX

Price (delayed)

$167.19

Market cap

$16.81B

P/E Ratio

24.92

Dividend/share

N/A

EPS

$6.71

Enterprise value

$16.95B

?
Relative Growth: Rel. Growth: 99
Relative Strength: Rel. Strength: 72
Relative Valuation: Rel. Valuation: 64
Relative Profitability: Rel. Profitability: 98

Neurocrine Biosciences is a publicly traded biopharmaceutical company founded in 1992. The company is headquartered in San Diego, California, and led by CEO Kevin Gorman. Neurocrine develops treatments for neurological ...

Highlights
NBIX's EPS has surged by 121% year-on-year and by 40% since the previous quarter
The company's net income has surged by 119% YoY and by 40% QoQ
Neurocrine Biosciences's quick ratio has decreased by 14% from the previous quarter and by 10% YoY
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.neurocrine.com/
Peers: RGEN RPRX ABBV PFE

Key stats

What are the main financial stats of NBIX

NBIX stock price

How has the Neurocrine Biosciences stock price performed over time
Intraday
1.26%
1 week
6.91%
1 month
24.7%
1 year
34.27%
YTD
17.88%
QTD
26.91%

Financial performance

How have Neurocrine Biosciences's revenue and profit performed over time
Revenue
$3.1B
Gross profit
$3.05B
Operating income
$760.3M
Net income
$668.6M
Gross margin
98.2%
Net margin
21.6%
The company's net income has surged by 119% YoY and by 40% QoQ
The net margin has soared by 70% YoY and by 29% QoQ
The operating income has surged by 54% year-on-year and by 23% since the previous quarter
Neurocrine Biosciences's revenue has increased by 29% YoY and by 8% QoQ

Price vs fundamentals

How does NBIX's price correlate with its fundamentals

Growth

What is Neurocrine Biosciences's growth rate over time

Valuation

What is Neurocrine Biosciences stock price valuation
NBIX P/E details
P/E
24.92
P/B
4.92
P/S
5.42
EV/EBIT
18.08
EV/EBITDA
17.01
EV/Sales
5.46
NBIX's EPS has surged by 121% year-on-year and by 40% since the previous quarter
The price to earnings (P/E) is 74% lower than the 5-year quarterly average of 93.4 and 17% lower than the last 4 quarters average of 29.5
The company's equity rose by 34% YoY and by 4.7% QoQ
NBIX's price to book (P/B) is 12% lower than its 5-year quarterly average of 5.5 but 10% higher than its last 4 quarters average of 4.4
Neurocrine Biosciences's revenue has increased by 29% YoY and by 8% QoQ
The stock's price to sales (P/S) is 16% less than its 5-year quarterly average of 6.4 but 11% more than its last 4 quarters average of 4.8

Efficiency

How efficient is Neurocrine Biosciences business performance
The ROE has soared by 83% YoY and by 29% from the previous quarter
Neurocrine Biosciences's return on assets has surged by 76% YoY and by 30% QoQ
The company's return on invested capital has surged by 72% YoY and by 26% QoQ
NBIX's return on sales has surged by 56% year-on-year and by 22% since the previous quarter

Dividends

What is NBIX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NBIX.

Financial health

How did Neurocrine Biosciences financials performed over time
NBIX's total assets is up by 33% YoY and by 6% from the previous quarter
The total liabilities has grown by 30% YoY and by 9% from the previous quarter
The debt is 88% lower than the equity
The company's equity rose by 34% YoY and by 4.7% QoQ
NBIX's debt to equity is down by 33% year-on-year and by 8% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.